Business Wire

CSG Cloud-Native Rating and Charging Solution Now in Production With Customers Worldwide

Share

CSG ® (NASDAQ: CSGS) today introduced a new addition to its Ascendon platform, CSG Ascendon Rating & Charging, a fully cloud-native, serverless charging software as a service (SaaS). Now actively in use, the solution provides CSG customers with real-time online charging functionality and rating capabilities to support and scale for wireless and digital services offered today and in the future.

As device types and connections surge, operators need highly flexible solutions to rate and charge for events in real-time, at scale, and for innovative monetization models. As a fully hosted, multi-tenant, SaaS solution architected on Amazon Web Services (AWS), Ascendon Rating and Charging elastically scales when volumes fluctuate allowing for efficient and cost-effective management of network resources.

The solution can be used to configure any combination of products, offers, and eligibility rules, as well as how they are sold across channels, in a matter of minutes. It enables balance sharing across multiple devices and services and gives operators the ability to charge dynamically based on network events, with real-time notifications to help engage the customer.

The solution also provides online charging system (OCS) capabilities including real-time authorization and balance management for voice, data, content and digital services; usage processing and rating; and dynamic entitlements that ensure accurate charging.

“Modern business models are centered around emerging digital offers that can be deployed quickly and cost effectively,” said Chad Dunavant, head of global product management, CSG. “CSG Ascendon Rating and Charging is a new breed of cloud-native SaaS that helps operators successfully deploy new services like 5G, while helping them manage risk and optimize operational costs.” (video)

Key technical features include:

  • Resiliency by design: High availability and geographically distributed across multiple AWS availability zones (AZs) to help ensure a fail-proof environment. It exceeds the resilience of traditional data centers by utilizing multiple AZs by design, providing a minimum of active-active-active configuration.
  • Grow as you go: Provides an unlimited supply of cloud-compute and scalability through AWS, taking the guesswork out of required capacity and eliminating the need for large upfront capital expenditures, lowering operational costs.
  • Fully featured and highly flexible: Configurable to support any wireless or digital service or bundled offer, as well as multiple charging models including pre-pay, post-pay, currency conversion, payments, invoicing, and adjustments.
  • Fully managed: Complete management of operations and issues, as well as automated quarterly releases deployed by CSG, allowing for rapid deployment of new features and efficient management of resources internally.
  • Network/platform agnostic: Charge for any transaction across any network or service platform.

This solution is part of CSG Ascendon, a globally recognized and award-winning digital monetization platform that has helped some of the world’s most innovative companies not just compete but thrive in the digital economy. Ascendon is part of CSG’s Revenue and Customer Management suite of end-to-end capabilities that support more than 500 companies globally, providing them with flexible and configurable technology solutions that help them monetize and digitally enable their customer experiences.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Brad Jones
Public Relations
CSG
+1 (303) 200-3001
brad.jones@csgi.com

David Banks
Investor Relations
CSG
+1 (303) 200-3127
david.banks@csgi.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release

Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye